More recently, the MM-302 formulation of PEGylated liposomal doxorubicin, which is targeted against the human epidermal growth factor receptor 2 (HER2), was assessed in clinical trials for advanced breast cancer 191. Here, ERBB2 is linked to breast carcinoma.